Amarin Reports Third Quarter 2025 Financial Results

Core Insights - Amarin Corporation has transitioned to a fully partnered commercialization model across all international markets, which is expected to enhance its operational efficiency and market reach [1][3] - The Q3 2025 financial results indicate a positive trend with a 17% increase in total net revenue compared to Q3 2024, driven primarily by strong U.S. sales [4][6] - The company aims to achieve sustainable positive free cash flow by 2026, reflecting confidence in its strategic actions and operational improvements [1][4] Financial Performance - Total net revenue for Q3 2025 was $49.7 million, up from $42.3 million in Q3 2024, marking a 17% increase [4][6] - Product revenue, net increased by 16% to $48.6 million, primarily due to higher U.S. sales, which rose by 34% to $40.9 million [5][7] - Operating expenses decreased by 20% to $33.3 million, largely due to a restructuring plan implemented in June 2025 [9][12] Operating Metrics - The operating loss for Q3 2025 was $11.1 million, significantly improved from a loss of $25.2 million in Q3 2024, reflecting a 56% reduction [4][14] - The net loss for Q3 2025 was $7.7 million, compared to a net loss of $25.1 million in the same quarter of the previous year, indicating a 69% improvement [15][34] - Cash and investments at the end of Q3 2025 totaled $286.6 million, down from $305.7 million in Q3 2024 [15] Strategic Initiatives - The company has established partnerships with seven parties across nearly 100 countries to leverage regional expertise and infrastructure for the commercialization of VASCEPA/VAZKEPA [3][17] - Amarin is focused on enhancing shareholder value through strategic actions and is optimistic about its global business potential [3][4]